SOD1 and amyotrophic lateral sclerosis: Given the apparent benefit of this pathway in clearing SOD1 aggregates (Kieran et al., 2004; Kalmar et al., 2008; Crippa et al., 2010; Lin et al., 2013), these data support the use of HSR agonists in the treatment of SOD1-linked ALS, such as the HSR inducing agent arimoclomol (Kieran et al., 2004; Kalmar et al., 2008, 2014).